(Q37142056)

18 August 2017

1 reference

title

A review of irritable bowel syndrome and an update on therapeutic approaches (English)

1 reference

18 August 2017

main subject

irritable bowel syndrome

1 reference

John T Bassett

1

1 reference

18 August 2017

Brooks D Cash

series ordinal

2

1 reference

18 August 2017

language of work or name

English

0 references

publication date

1 May 2008

1 reference

Expert Opinion on Pharmacotherapy

18 August 2017

published in

1 reference

18 August 2017

volume

9

1 reference

18 August 2017

issue

7

1 reference

18 August 2017

page(s)

1129-1143

1 reference

Functional bowel disorders

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1129

The burden of selected digestive diseases in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1129

Irritable bowel syndrome in Germany. A cost of illness study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1129

Alterations in cerebral potentials evoked by rectal distension in irritable bowel syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1129

Alterations of brain activity associated with resolution of emotional distress and pain in a case of severe irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1129

Novel evidence for hypersensitivity of visceral sensory neural circuitry in irritable bowel syndrome patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1129

Infection, immune function, and functional gut disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1129

Small intestinal bacterial overgrowth: a framework for understanding irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1129

New pathophysiological mechanisms in irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1129

Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1129

Mast cell stabilizer ketotifen [4-(1-methyl-4-piperidylidene)-4h-benzo[4,5]cyclohepta[1,2-b]thiophen-10(9H)-one fumarate] prevents mucosal mast cell hyperplasia and intestinal dysmotility in experimental Trichinella spiralis inflammation in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1129

Is irritable bowel syndrome a low-grade inflammatory bowel disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1129

Irritable bowel syndrome: relationship of disorders in the transit of a single solid meal to symptom patterns

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1129

Systematic review of the comorbidity of irritable bowel syndrome with other disorders: what are the causes and implications?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1129

AGA technical review on irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1129

The utility of diagnostic tests in irritable bowel syndrome patients: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1129

Additional investigations fail to alter the diagnosis of irritable bowel syndrome in subjects fulfilling the Rome criteria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1129

Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1129

Meta-analysis: The treatment of irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1129

Systematic review: the role of different types of fibre in the treatment of irritable bowel syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1129

Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1129

Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1129

The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1129

Paroxetine to treat irritable bowel syndrome not responding to high-fiber diet: a double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1129

A controlled crossover study of the selective serotonin reuptake inhibitor citalopram in irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1129

Effect of a corticotropin releasing hormone receptor antagonist on colonic sensory and motor function in patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1129

Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1129

Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1129

Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1129

Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1129

Cilansetron: a new serotonergic agent for the irritable bowel syndrome with diarrhoea

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1129

A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1129

An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1129

Effect of renzapride on transit in constipation-predominant irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1129

Interleukin 10 genotypes in irritable bowel syndrome: evidence for an inflammatory component?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1129

The cardiovascular safety profile of renzapride, a novel treatment for irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1129

Alvimopan, a selective peripherally acting mu-opioid antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1129

Alvimopan, a peripherally acting mu-opioid receptor antagonist, compared with placebo in postoperative ileus after major abdominal surgery: results of a randomized, double-blind, controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1129

Phase III trial of alvimopan, a novel, peripherally acting, mu opioid antagonist, for postoperative ileus after major abdominal surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1129

Effect of asimadoline, a kappa opioid agonist, on pain induced by colonic distension in patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1129

A novel tachykinin NK2 receptor antagonist prevents motility-stimulating effects of neurokinin A in small intestine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1129

Neurokinin NK1 and NK3 receptors as targets for drugs to treat gastrointestinal motility disorders and pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1129

A randomized, controlled exploratory study of clonidine in diarrhea-predominant irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1129

Autoradiographic localization and quantitative determination of specific binding sites of anxiolytic homophthalazines (formerly called 2,3-benzodiazepines) in the striato-pallido-nigral system of rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1129

Anxiolytic 2,3-benzodiazepines, their specific binding to the basal ganglia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1129

Neomycin improves constipation-predominant irritable bowel syndrome in a fashion that is dependent on the presence of methane gas: subanalysis of a double-blind randomized controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1129

Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1129

Intrarectal lidocaine is an effective treatment for abdominal pain associated with diarrhea-predominant irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1129

Gabapentin in postherpetic neuralgia: a randomised, double blind, placebo controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1129

Gabapentin reduces rectal mechanosensitivity and increases rectal compliance in patients with diarrhoea-predominant irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1129

Effect of a second-generation alpha2delta ligand (pregabalin) on visceral sensation in hypersensitive patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1129

Single-blind follow-up study on the effectiveness of a symbiotic preparation in irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1129

Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1129

A one year follow-up of relaxation response meditation as a treatment for irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1129

Systematic review: the effectiveness of hypnotherapy in the management of irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1129

Rectal hypersensitivity reduced by acupoint TENS in patients with diarrhea-predominant irritable bowel syndrome: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1129

Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1129

10.1517/14656566.9.7.1129

21 January 2018

Identifiers

DOI

1 reference

18 August 2017

1 reference